NL1033520A1 - Ghrelinebindende nucleïnezuren. - Google Patents

Ghrelinebindende nucleïnezuren.

Info

Publication number: NL1033520A1
Authority: NL; Netherlands
Prior art keywords: nucleic acids; binding nucleic; ghrelin binding; ghrelin; acids
Prior art date: 2005-04-08

Application number

NL1033520A

Other languages

English (en)

Other versions

NL1033520C2 (nl

Inventor

Florian Jarosch

Dirk Eulberg

Christian Maasch

Steffen Helmling

Sven Klussmann

Original Assignee

Noxxon Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-04-08

Filing date

2007-03-08

Publication date

2007-08-06

2007-03-08 Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag

2007-08-06 Publication of NL1033520A1 publication Critical patent/NL1033520A1/nl

2010-01-21 Application granted granted Critical

2010-01-21 Publication of NL1033520C2 publication Critical patent/NL1033520C2/nl

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6811—Selection methods for production or design of target specific oligonucleotides or binding molecules
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
- C12N2310/3183—Diol linkers, e.g. glycols or propanediols
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Wood Science & Technology (AREA)
Diabetes (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Microbiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Obesity (AREA)
Hematology (AREA)
Plant Pathology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Analytical Chemistry (AREA)
Immunology (AREA)
Child & Adolescent Psychology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)

NL1033520A 2005-04-08 2007-03-08 Ghrelinebindende nucleïnezuren. NL1033520C2 (nl)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP05007795		2005-04-08
EP05007795		2005-04-08

Publications (2)

Publication Number	Publication Date
NL1033520A1 true NL1033520A1 (nl)	2007-08-06
NL1033520C2 NL1033520C2 (nl)	2010-01-21

Family

ID=37087373

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NL1031538A NL1031538C2 (nl)	2005-04-08	2006-04-07	Ghrelinebindende nucleïnezuren.
NL1033520A NL1033520C2 (nl)	2005-04-08	2007-03-08	Ghrelinebindende nucleïnezuren.

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NL1031538A NL1031538C2 (nl)	2005-04-08	2006-04-07	Ghrelinebindende nucleïnezuren.

Country Status (24)

Country	Link
US (2)	US8101734B2 (nl)
EP (1)	EP1866412A2 (nl)
JP (2)	JP5308813B2 (nl)
KR (1)	KR20080009072A (nl)
CN (1)	CN101189337B (nl)
AP (1)	AP2007004189A0 (nl)
AR (1)	AR052741A1 (nl)
AU (1)	AU2006233647A1 (nl)
BR (1)	BRPI0608180A2 (nl)
CA (1)	CA2605377A1 (nl)
CR (1)	CR9423A (nl)
DO (1)	DOP2006000085A (nl)
EA (1)	EA200701901A1 (nl)
GB (1)	GB2439673A (nl)
GT (1)	GT200600137A (nl)
IL (1)	IL186085A0 (nl)
MA (1)	MA29384B1 (nl)
MX (1)	MX2007012419A (nl)
NL (2)	NL1031538C2 (nl)
PE (1)	PE20061358A1 (nl)
TN (1)	TNSN07375A1 (nl)
TW (1)	TW200718781A (nl)
UY (1)	UY29460A1 (nl)
WO (1)	WO2006108599A2 (nl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1530635B1 (en) *	2002-08-01	2011-06-15	Noxxon Pharma AG	Ghrelin binding nucleic acids
CN1894407A (zh) *	2003-11-10	2007-01-10	诺松制药股份公司	特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es)	2005-04-08	2007-03-28	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin
EP2274331B1 (en)	2008-05-02	2013-11-06	Novartis AG	Improved fibronectin-based binding molecules and uses thereof
US8796216B2 (en) *	2008-06-12	2014-08-05	Syntaxin Limited	Suppression of neuroendocrine diseases
WO2011051327A2 (en)	2009-10-30	2011-05-05	Novartis Ag	Small antibody-like single chain proteins
WO2011051466A1 (en)	2009-11-02	2011-05-05	Novartis Ag	Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011092233A1 (en)	2010-01-29	2011-08-04	Novartis Ag	Yeast mating to produce high-affinity combinations of fibronectin-based binders
ES2748038T3 (es)	2011-07-01	2020-03-12	Ngm Biopharmaceuticals Inc	Composiciones, usos y métodos para el tratamiento de trastornos y enfermedades metabólicos
EP2925775B1 (en)	2012-11-28	2020-09-16	NGM Biopharmaceuticals, Inc.	Compositions and methods for treatment of metabolic disorders and diseases
EP2938740B1 (en)	2012-12-27	2022-04-20	NGM Biopharmaceuticals, Inc.	Chimeric fgf19 peptides for use in treating bile acid disorders
RU2679889C2 (ru)	2013-04-18	2019-02-14	Армо Байосайенсиз, Инк.	Способы применения интерлейкина-10 для лечения заболеваний и расстройств
US9823255B2 (en)	2013-06-17	2017-11-21	Armo Biosciences, Inc.	Method for assessing protein identity and stability
WO2015031316A1 (en)	2013-08-30	2015-03-05	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
CN105848674A (zh)	2013-11-11	2016-08-10	阿尔莫生物科技股份有限公司	将白细胞介素-10用于治疗疾病和病症的方法
WO2015077717A1 (en)	2013-11-25	2015-05-28	The Broad Institute Inc.	Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en)	2013-12-05	2023-08-15	The Broad Institute Inc.	Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en)	2013-12-20	2016-10-26	The Broad Institute, Inc.	Combination therapy with neoantigen vaccine
US9119832B2 (en)	2014-02-05	2015-09-01	The Regents Of The University Of California	Methods of treating mild brain injury
CN106573072A (zh)	2014-06-02	2017-04-19	阿尔莫生物科技股份有限公司	降低血清胆固醇的方法
WO2016060996A2 (en)	2014-10-14	2016-04-21	Armo Biosciences, Inc.	Interleukin-15 compositions and uses thereof
MX2017004983A (es)	2014-10-22	2017-11-13	Armo Biosciences Inc	Metodos para usar interleucina 10 para tratar enfermedades y trastornos.
IL251834B2 (en)	2014-10-23	2023-09-01	Ngm Biopharmaceuticals Inc	Pharmaceutical compositions containing peptide variants and methods of using them
US10993997B2 (en)	2014-12-19	2021-05-04	The Broad Institute, Inc.	Methods for profiling the t cell repertoire
EP3234193B1 (en)	2014-12-19	2020-07-15	Massachusetts Institute of Technology	Molecular biomarkers for cancer immunotherapy
WO2016126615A1 (en)	2015-02-03	2016-08-11	Armo Biosciences, Inc.	Methods of using interleukin-10 for treating diseases and disorders
WO2016187508A2 (en)	2015-05-20	2016-11-24	The Broad Institute Inc.	Shared neoantigens
JP7121496B2 (ja)	2015-05-28	2022-08-18	アルモ・バイオサイエンシーズ・インコーポレイテッド	癌治療で使用するためのペグ化インターロイキン－１０
JP7053453B2 (ja)	2015-08-25	2022-04-12	アルモ・バイオサイエンシーズ・インコーポレイテッド	疾患及び障害を治療するためのインターロイキン１０の使用方法
ES2871036T3 (es)	2015-11-09	2021-10-28	Ngm Biopharmaceuticals Inc	Método para el tratamiento de trastornos relacionados con ácidos biliares
US20190307868A1 (en)	2016-03-31	2019-10-10	Neon Therapeutics, Inc.	Neoantigens and methods of their use
EP3446119A1 (en)	2016-04-18	2019-02-27	The Broad Institute Inc.	Improved hla epitope prediction
US11549149B2 (en)	2017-01-24	2023-01-10	The Broad Institute, Inc.	Compositions and methods for detecting a mutant variant of a polynucleotide
BR112019016657A2 (pt)	2017-02-12	2020-04-07	Neon Therapeutics, Inc.	métodos baseados em hla e composições e usos destes
CN111315398A (zh)	2017-11-10	2020-06-19	阿尔莫生物科技股份有限公司	白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法
TW201930340A (zh)	2017-12-18	2019-08-01	美商尼恩醫療公司	新抗原及其用途
US20210347842A1 (en)	2018-06-19	2021-11-11	Eli Lilly And Company	Compositions and methods of use of il-10 agents in conjunction with chimeric antigen receptor cell therapy
US20210382068A1 (en)	2018-10-02	2021-12-09	Dana-Farber Cancer Institute, Inc.	Hla single allele lines
AU2019365382B2 (en)	2018-10-24	2024-02-08	F. Hoffmann-La Roche Ag	Process for the purification of oligonucleotides
WO2020131586A2 (en)	2018-12-17	2020-06-25	The Broad Institute, Inc.	Methods for identifying neoantigens
SG11202106678PA (en)	2018-12-21	2021-07-29	Biontech Us Inc	Method and systems for prediction of hla class ii-specific epitopes and characterization of cd4+ t cells
JP7726067B2 (ja) *	2019-06-11	2025-08-20	味の素株式会社	ペプチド及びその用途
JP2022536695A (ja)	2019-06-12	2022-08-18	ビオンテックユーエスインコーポレイテッド	新抗原組成物およびその使用
US12394502B2 (en)	2019-10-02	2025-08-19	The General Hospital Corporation	Method for predicting HLA-binding peptides using protein structural features
WO2022032228A1 (en)	2020-08-07	2022-02-10	The Broad Institute, Inc.	Therapeutic targeting of phosphate dysregulation in cancer via the xpr1:kidins220 protein complex
CN117083081A (zh)	2020-12-14	2023-11-17	百欧恩泰美国公司	用于癌症免疫疗法的组织特异性抗原
EP4598949A1 (en)	2022-10-07	2025-08-13	The General Hospital Corporation	Methods and compositions for high-throughput discovery of peptide-mhc targeting binding proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5614395A (en) *	1988-03-08	1997-03-25	Ciba-Geigy Corporation	Chemically regulatable and anti-pathogenic DNA sequences and uses thereof
US6232071B1 (en) *	1990-06-11	2001-05-15	Gilead Sciences, Inc.	Tenascin-C nucleic acid ligands
ATE318832T1 (de) *	1990-06-11	2006-03-15	Gilead Sciences Inc	Verfahren zur vervendung von nukleinsäureliganden
JPH11505527A (ja)	1995-05-03	1999-05-21	ホワイトヘッドインスティチュートフォーバイオメディカルリサーチ	鏡像異性体リガンドの同定
DE19808591C2 (de)	1998-02-28	2000-02-03	Univ Leipzig	Standardisierter durchflußzytometrischer Vollblutassay
US20030211967A1 (en) *	2001-05-07	2003-11-13	Bryant Henry Uhlman	Method for selectively inhibiting ghrelin action
AU2001259056A1 (en)	2000-05-17	2001-11-26	Eli Lilly And Company	Method for selectively inhibiting ghrelin action
EP1353683A4 (en)	2000-05-30	2004-05-12	Merck & Co Inc	ANALOGS BY GHRELIN
US7629456B2 (en) *	2001-10-26	2009-12-08	Noxxon Pharma Ag	Modified L-nucleic acid
EP1530635B1 (en) *	2002-08-01	2011-06-15	Noxxon Pharma AG	Ghrelin binding nucleic acids
CN1894407A (zh)	2003-11-10	2007-01-10	诺松制药股份公司	特异性结合生物活性生长素释放肽的核酸
AR052741A1 (es)	2005-04-08	2007-03-28	Noxxon Pharma Ag	Acidos nucleicos de union a ghrelin

2006
- 2006-04-06 AR ARP060101371A patent/AR052741A1/es not_active Application Discontinuation
- 2006-04-06 UY UY29460A patent/UY29460A1/es not_active Application Discontinuation
- 2006-04-07 TW TW095112321A patent/TW200718781A/zh unknown
- 2006-04-07 NL NL1031538A patent/NL1031538C2/nl not_active IP Right Cessation
- 2006-04-07 PE PE2006000380A patent/PE20061358A1/es not_active Application Discontinuation
- 2006-04-07 GT GT200600137A patent/GT200600137A/es unknown
- 2006-04-07 US US11/400,459 patent/US8101734B2/en not_active Expired - Fee Related
- 2006-04-07 DO DO2006000085A patent/DOP2006000085A/es unknown
- 2006-04-10 MX MX2007012419A patent/MX2007012419A/es active IP Right Grant
- 2006-04-10 AP AP2007004189A patent/AP2007004189A0/xx unknown
- 2006-04-10 EP EP06724207A patent/EP1866412A2/en not_active Withdrawn
- 2006-04-10 EA EA200701901A patent/EA200701901A1/ru unknown
- 2006-04-10 BR BRPI0608180-0A patent/BRPI0608180A2/pt not_active IP Right Cessation
- 2006-04-10 CN CN2006800199540A patent/CN101189337B/zh not_active Expired - Fee Related
- 2006-04-10 JP JP2008504702A patent/JP5308813B2/ja not_active Expired - Fee Related
- 2006-04-10 WO PCT/EP2006/003276 patent/WO2006108599A2/en not_active Ceased
- 2006-04-10 AU AU2006233647A patent/AU2006233647A1/en not_active Abandoned
- 2006-04-10 CA CA002605377A patent/CA2605377A1/en not_active Abandoned
- 2006-04-10 GB GB0719489A patent/GB2439673A/en not_active Withdrawn
- 2006-04-10 KR KR1020077023000A patent/KR20080009072A/ko not_active Abandoned
2007
- 2007-03-08 NL NL1033520A patent/NL1033520C2/nl not_active IP Right Cessation
- 2007-09-19 IL IL186085A patent/IL186085A0/en unknown
- 2007-10-05 TN TNP2007000375A patent/TNSN07375A1/fr unknown
- 2007-10-08 CR CR9423A patent/CR9423A/es not_active Application Discontinuation
- 2007-10-08 MA MA30282A patent/MA29384B1/fr unknown
2012
- 2012-01-24 US US13/356,816 patent/US20120115937A1/en not_active Abandoned
2013
- 2013-04-05 JP JP2013079688A patent/JP2013176372A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
CN101189337A (zh)	2008-05-28
WO2006108599A3 (en)	2007-02-15
US8101734B2 (en)	2012-01-24
AU2006233647A1 (en)	2006-10-19
EA200701901A1 (ru)	2008-04-28
GT200600137A (es)	2006-11-22
CA2605377A1 (en)	2006-10-19
NL1031538C2 (nl)	2007-03-20
UY29460A1 (es)	2006-11-30
IL186085A0 (en)	2008-01-20
NL1031538A1 (nl)	2006-10-10
CN101189337B (zh)	2013-11-06
MA29384B1 (fr)	2008-04-01
US20120115937A1 (en)	2012-05-10
KR20080009072A (ko)	2008-01-24
WO2006108599A2 (en)	2006-10-19
AP2007004189A0 (en)	2007-10-31
EP1866412A2 (en)	2007-12-19
JP5308813B2 (ja)	2013-10-09
US20060258607A1 (en)	2006-11-16
MX2007012419A (es)	2007-12-05
NL1033520C2 (nl)	2010-01-21
TNSN07375A1 (fr)	2009-03-17
CR9423A (es)	2007-12-17
TW200718781A (en)	2007-05-16
PE20061358A1 (es)	2007-01-13
BRPI0608180A2 (pt)	2009-11-17
JP2008534024A (ja)	2008-08-28
GB0719489D0 (en)	2007-11-21
JP2013176372A (ja)	2013-09-09
AR052741A1 (es)	2007-03-28
AU2006233647A2 (en)	2008-04-17
GB2439673A (en)	2008-01-02
DOP2006000085A (es)	2006-11-15

Publication	Publication Date	Title
NL1033520A1 (nl)	2007-08-06	Ghrelinebindende nucleïnezuren.
CY2020009I1 (el)	2020-11-25	Δεσμευτικοι παραγοντες σκληροστινης
NL300935I2 (nl)	2018-10-25	guselkumab.
NL1028967A1 (nl)	2005-11-08	4-Fenylamino-chinazoline-6-yl-amiden.
NO20051199L (no)	2006-09-08	Rorhandteringsutstyr.
NO20041374D0 (no)	2004-04-02	Bolgekraftverk.
NO20052535D0 (no)	2005-05-27	Polynucleotide.
NO20040762L (no)	2005-08-22	Stromskinne.
NO20053362D0 (no)	2005-07-11	Syklofuge.
ITVE20050008U1 (it)	2006-09-15	Elemento riscaldante.
ES1056663Y (es)	2004-08-01	Abrazadera.
ITRM20050027A1 (it)	2006-07-22	Munizione.
NL1028622A1 (nl)	2005-09-27	Stelwig.
NL1025196A1 (nl)	2004-02-24	Hark-Zeef-Vork.
FI20050547A0 (fi)	2005-05-24	Side
FI20050349A0 (fi)	2005-04-06	Sidontalaite
FI20050927A0 (fi)	2005-09-16	Sidontalaite
FI20050718A0 (fi)	2005-07-05	Sidontalaite
FI20050009A0 (fi)	2005-01-05	Sidontalaite
ES1057576Y (es)	2004-12-16	Grapa centrador.
NO20053098D0 (no)	2005-06-24	Forbedret limsystem.
ES1060050Y (es)	2005-11-01	Palillo pinza.
FI20041026A0 (fi)	2004-07-27	Sidontalaite
FI20041350A0 (fi)	2004-10-19	Sidontalaite
ITPZ20040010A1 (it)	2004-10-09	Eco-power a1.

Legal Events

Date	Code	Title	Description
2007-10-01	AD1A	A request for search or an international type search has been filed
2010-03-01	PD2A	A request for search or an international type search has been filed
2010-11-10	V1	Lapsed because of non-payment of the annual fee	Effective date: 20101101